drugset
drugset / Trial / NCT04014361

A Study of LY3154885 in Healthy Participants

NCT04014361 ↗

Phase 1 Terminated 36 enrolled Eli Lilly and Company
RandomizedSequentialDouble-blindBasic science

Summary

The main purpose of this study is to learn more about the safety and side effects of LY3154885 when given by mouth to healthy participants. The study will have up to four parts. Each participant will enroll in only one part. The study will last up to 70 days for each participant, including screening and follow-up.

Timeline

Start
2019-08-09
Primary completion
2020-02-09
Completion
2020-02-09

Outcome

Outcome not reported

Stopped (Business): “HUAA study is terminated early due to a business decision.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Itraconazole Small molecule 200 mg Oral
Background LY3154885 Unknown 15 mg Oral
Background LY3154885 Unknown 45 mg Oral
Background LY3154885 Unknown 100 mg Oral
Background LY3154885 Unknown 200 mg Oral
Background LY3154885 Unknown 300 mg Oral
Background LY3154885 Unknown 375 mg Oral
Background LY3154885 Unknown — Oral

Indications

No indication recorded.